World Health Organization Raises Concern Over Critical Lack of Weight-Loss Medications
Under 10% of individuals who could benefit from weight-loss injections including Wegovy are able to get them, caution the WHO as it releases its first advice on the drugs.
Considering in excess of 1,000,000,000 people worldwide currently living with obesity, it is advocating for increased and just access to this class of drugs.
Based on forecasts, in excess of 2,000,000,000 could be living with obesity by 2030 unless action is taken.
"Our new guidance acknowledges that excess weight is a chronic disease that can be treated with thorough and ongoing care," said WHO director-general Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and logistical bottlenecks are key barriers to broad availability to the jabs that can help people shift significant body mass, says the body.
Weight-Loss Drug Supply Crisis
Even under the present most favorable scenario, the manufacturing of such drugs could only cover about 100 million people – less than 10% of the global need, as stated by the WHO.
The advice encourages governments and firms to increase availability, via strategies such as licensing agreements.
A patent on the active ingredient – the core component of Novo Nordisk's Wegovy – is due to expire in a number of countries in 2026.
How Obesity Drugs Work
These medications imitate a natural hormone to reduce digestion speed, curb appetite and increase feelings of fullness so users eat less.
Individuals typically begin shedding pounds in the initial weeks of beginning the regular doses.
Evidence suggests people may regain a significant portion after a year of discontinuing the drug, because their usual food cravings come back.
Being carrying excess weight increases your chance for contracting health problems, such as type 2 diabetes, cardiovascular issues, stroke, and specific cancers.
Obesity concerns individuals in countries worldwide and was linked to over three and a half million deaths worldwide in 2024, per the health agency.
